Eli Lilly Opposes Push to Pass Trump's Drug Pricing Deals Into Law, CEO Says

Why It Matters

Codifying MFN pricing threatens pharmaceutical revenue streams that fund R&D, potentially slowing the launch of new therapies and reshaping the U.S. drug market.

Key Takeaways

• Lilly opposes codifying MFN pricing into law
• Over a dozen pharma firms signed MFN deals with Trump
• CEO warns policy could stifle future drug innovation
• Company will use lobbying and legal tools against proposal
• MFN pricing aims to align US drug prices with peers

Pulse Analysis

The Trump administration’s “most‑favored‑nation” (MFN) framework, unveiled in 2025, asked manufacturers to price U.S. prescriptions no higher than those in other affluent markets such as the EU, Canada, and Japan. More than a dozen pharmaceutical giants, including Eli Lilly, signed voluntary agreements last year to demonstrate goodwill and defuse political pressure. Now the White House is moving to embed those commitments in legislation, a step that would shift a soft‑policy promise into binding law. Industry observers see this as a test of the administration’s ability to reshape drug‑pricing rules.

Eli Lilly’s chief executive Dave Ricks warned that codifying MFN pricing could erode the financial incentives needed for next‑generation therapies. By capping U.S. prices to foreign levels, the company argues, revenue streams essential for costly research and development would shrink, potentially delaying breakthroughs in oncology, diabetes, and immunology. Lilly has pledged to deploy “all the tools” at its disposal—intensive lobbying, strategic litigation, and public‑relations campaigns—to challenge what it calls “bad policy.” The stance mirrors a broader industry coalition that fears a precedent‑setting price ceiling.

The debate pits consumer‑price relief against the risk of dampening innovation pipelines. If Congress adopts MFN language, drugmakers may recalibrate global launch strategies, possibly delaying U.S. introductions or raising prices elsewhere to offset reduced margins. Investors are watching closely, as any shift in pricing policy could affect earnings forecasts for the sector’s biggest players. Meanwhile, bipartisan lawmakers remain split, with some championing immediate affordability and others urging caution to preserve America’s competitive edge in pharmaceutical research.